Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.89 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15067033 | 1.00 | KDM4E (0.89) | KDM4ELMNAGAAACEALDH1A1 | |
| SCHEMBL15068257 | 1.00 | KDM4E (0.89) | KDM4ELMNAGAAACEALDH1A1 | |
| SCHEMBL15476567 | 0.81 | KDM4E (0.61) | KDM4ELMNAGAAACEALDH1A1 | |
| SCHEMBL14862459 | 0.81 | KDM4E (0.61) | KDM4ELMNAGAAACEALDH1A1 | |
| SCHEMBL2551746 | 0.81 | KDM4E (0.61) | KDM4ELMNAGAAACEALDH1A1 | |
| SCHEMBL15476970 | 0.81 | KDM4E (0.61) | KDM4ELMNAGAAACEALDH1A1 | |
| SCHEMBL15476952 | 0.79 | KDM4E (0.58) | KDM4ELMNAALDH1A1TSHRMEN1 | |
| SCHEMBL14862404 | 0.79 | KDM4E (0.58) | KDM4ELMNAALDH1A1TSHRMEN1 | |
| SCHEMBL13291353 | 0.78 | KDM4E (0.56) | KDM4ELMNAALDH1A1CYP2D6CHRM3 | |
| SCHEMBL14257980 | 0.78 | KDM4E (0.56) | KDM4ELMNAALDH1A1CYP2D6CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748613-B2 | Quinuclidine esters of 1-azaheterocyclylacetic acid as antimuscarinic agents, process for their preparation and medicinal compositions thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-06-10 | — | — | US | disclosed |
| US-20130172302-A1 | QUINUCLIDINE ESTERS OF 1-AZAHETEROCYCLYLACETIC ACID AS ANTIMUSCARINIC AGENTS, PROCESS FOR THEIR PREPARATION AND MEDICINAL COMPOSITIONS THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172302-A1 | QUINUCLIDINE ESTERS OF 1-AZAHETEROCYCLYLACETIC ACID AS ANTIMUSCARINIC AGENTS, PROCESS FOR THEIR PREPARATION AND MEDICINAL COMPOSITIONS THEREOF | CHRM1, CHRM2, CHRM3 | KDM4E 2834/4885LMNA 1936/4885GAA 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.